ABIONYX Pharma S.A.
ABNX.PA · PAR
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -1.09 | 0.54 | 0.33 | -0.06 |
| FCF Yield | -8.98% | -10.11% | -7.34% | -11.27% |
| EV / EBITDA | -8.04 | -7.67 | -12.00 | -7.80 |
| Quality | ||||
| ROIC | -41.03% | -29.10% | -23.16% | -36.93% |
| Gross Margin | 18.35% | 13.32% | 12.11% | 38.37% |
| Cash Conversion Ratio | 0.82 | 1.05 | 0.80 | 1.15 |
| Growth | ||||
| Revenue 3-Year CAGR | -4.32% | 90.14% | – | – |
| Free Cash Flow Growth | 5.96% | -8.32% | 48.47% | -818.07% |
| Safety | ||||
| Net Debt / EBITDA | 0.10 | 0.15 | 0.01 | 0.40 |
| Interest Coverage | -91.34 | -179.58 | -17.12 | -48.00 |
| Efficiency | ||||
| Inventory Turnover | 17.54 | 18.20 | 31.40 | 2.35 |
| Cash Conversion Cycle | 42.22 | 85.73 | -44.76 | -1,369.65 |